<DOC>
	<DOCNO>NCT00761605</DOCNO>
	<brief_summary>The purpose study investigate efficacy flexibly dose paliperidone extended-release ( mechanism dissolve drug time order release slow steadier blood stream ) improve maintain subjective symptom participant three participant ' group ( , reason switch : lack efficacy group , lack tolerability group , lack compliance group ) switch previous antipsychotic drug paliperidone extended-release tablet flexible dos .</brief_summary>
	<brief_title>Phase 4 Study Evaluate Efficacy Paliperidone Extended-Release ( ER ) Schizophrenic Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , prospective ( study follow participant forward time ) , single arm , non-comparative study paliperidone Extended-release ( ER ) participant switch previous oral antipsychotic flexibly dose paliperidone ER . The total study duration approximately 24 week per participant . The study consist 2 part : Screening ( , 14 day study commences Day 1 ) ; Treatment ( 24 week ) . Efficacy primarily evaluate change baseline symptom checklist 90-R ( SCL90-R ) Week 24 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Childbearing potential woman consent use consistently permissible contraception ( oral contraceptive , contraceptive injection , intrauterine device , double barrier method contraceptive patch ) Participants compliant selfmedication receive consistent help support Participants need change antipsychotic drug another one follow reason among participant treat antipsychotic drug two week screen ( 1 ) Group lack efficacy : The antipsychotic drug clinically require change little therapeutic response despite appropriately dose antipsychotic therapy ( 2 ) Group lack tolerance : The antipsychotic drug require change due lack tolerance exist antipsychotic drug safety issue ( 3 ) Group lack compliance : The antipsychotic drug require change due lack medication compliance participant want change antipsychotic drug ) Participants past history neuroleptic malignant syndrome ( NMS ) Participants suspicious clinically significant risk include suicide aggressive behavior expect unable complete study ( base investigator 's judgment ) Participants severe preexist gastrointestinal narrowing ( pathologic iatrogenic ) participant swallow drug whole ( The study drug must chew , divide , melt grind impact study drug release profile Female participant pregnant breast feeding Participants participate investigational drug trial within 1 month prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Paliperidone extended-release</keyword>
	<keyword>Antipsychotics Agents</keyword>
</DOC>